Affini-T Therapeutics, Inc.

Founded in 2020, and based in Massachusetts, the US, Affini-T Therapeutics, Inc. operates as a biotechnology company that is developing T-cell therapies for cancer patients. Jak Knowles (CEO), Loïc Vincent (CSO), Kim Nguyen, (CTO), and Kathy Yi (COO) are the co-founders of the company. In March 2022, Affini-T Therapeutics, Inc.

raised USD 175 million in venture funding co-led by Vida Ventures and Leaps by Bayer including Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures, and Fred Hutchinson Cancer Research Center. The company offers a therapeutics platform that provides immune cell technology that unlocks the power of T cells while targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. The firm's cell therapy platform uses cutting-edge engineering and synthetic biology to optimize T-cell functions and rewrite the rules of the solid tumor microenvironment, allowing for the possibility of long-term clinical outcomes in patients. The organization plans to use the March 2022 funding to accelerate its growth by further developing its platform discovery engine and continuing to pursue complementary technology licenses to bolster its cell therapy platform.